

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED

通用環球醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code : 2666)

UNAUDITED OPERATION SUMMARY OF THE GROUP FOR THE THIRD QUARTER OF 2025

This announcement sets out the unaudited operation summary of Genertec Universal Medical Group Company Limited (the “**Company**” or “**Genertec Universal Medical**”), together with its subsidiaries (the “**Group**”), for the third quarter ended 30 September 2025.

This announcement is made pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

During the first three quarters of 2025, the Group’s overall operation was stable and improving, with substantial progress in key areas. For the nine months ended 30 September 2025, the revenue of the Group increased by approximately 12.8% as compared with the corresponding period of 2024, with the profit for the period increased of approximately 7.6% as compared with the corresponding period of 2024, while the profit for the period attributable to owners of the parent increased by approximately 4.2% as compared with the corresponding period of 2024.

In respect of integrated healthcare business, the Group proactively responded to policy impacts such as healthcare payment reforms, stricter fund supervision, and the volume-based procurement of pharmaceuticals and consumables. By enhancing its healthcare service capabilities and focusing on specialty- and disease-type-based refined management, the Group explored standardised treatment for specific diseases to drive quality and efficiency improvements in its operations. The medical institutions affiliated with the Group performed well in the first three quarters of 2025: through the in-depth implementation of holiday clinics, extended-hour clinics, specialist clinics and specialised clinics, outpatient and emergency visits increased against the trend by approximately 3.4% as compared with the corresponding period of 2024; by continuously optimising the treatment service processes based on the lean management concept, the total number of discharged patients increased by approximately 1.7% as compared with the corresponding period of 2024, and the average length of hospital stay was

reduced to 9.1 days, indicating a continuous improvement in operational efficiency; through the establishment of scientific, effective, reasonable and unified clinical pathways for specific diseases, the proportion of healthcare services revenue reached 36.5%, representing an increase of 2.3 percentage points as compared with the corresponding period of 2024, reflecting a significant optimisation in business structure; by strengthening cost control with a focus on the management of pharmaceuticals and consumables and carrying out targeted initiatives, the proportion of medicine and consumables costs to revenue was reduced from 44.9% to 43.0%, effectively enhancing the risk resilience and sustainable development capabilities of the medical institutions.

In respect of specialised medical care and healthcare technology, the Group focuses on core medical resources, adheres to the "dual-wheel drive" of internal development and external expansion, cultivates its specialty businesses and core competencies, and strives to build the second growth curve. Currently, this segment has made continuous progress in areas such as business layout expansion and capability building, and the relevant acquisition projects are also progressing smoothly.

In respect of finance business, the Group adheres to its functional positioning of serving the real economy and supporting the development of its core business, makes steady progress in the transformation and innovation of finance business and accelerates the business transformation towards four strategic directions, namely, medical health and elder care, equipment manufacturing, chemical pharmaceutical business and innovative business, innovates the new mode of industry-finance integration for "finance leasing + life cycle management" of medical equipment, and promotes the development of ageing finance and digital finance business by leveraging on the industrial resources while promoting the steady upgrading of traditional business. As at 30 September 2025, total interest-earning assets of the Group remained stable as compared with the beginning of 2025, with steady improvement in net interest margin and net interest spread. Asset quality still remained stable and controllable, and the provision coverage remained prudent.

The Company hereby reminds investors that the above unaudited operation summary for the third quarter ended 30 September 2025 was prepared based on the Group's internal figures and management accounts which have not been reviewed or audited by the auditors of the Group.

Investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Genertec Universal Medical Group Company Limited
通用環球醫療集團有限公司
Chen Shisu
Chairman of the Board

Beijing, PRC, 30 October 2025

As at the date of this announcement, the executive directors of the Company are Mr. Chen Shisu (Chairman), Mr. Wang Wenbing and Ms. Wang Lin; the non-executive directors of the Company are Mr. Tong Chaoyin, Mr. Lin Chunhai and Mr. Zhu Ziyang; and the independent non-executive directors of the Company are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas.